Perioperative chemotherapy regimens for muscle-invasive bladder cancer are evaluated in this editorial comment based on a reconstructed individual patient data analysis of phase 3 trials.
Tasa de eventos absoluta: 0% vs 0%
The author declares no conflicts of interest.
Yusuke Goto (Sun,) reported a other. Perioperative chemotherapy regimens for muscle-invasive bladder cancer are evaluated in this editorial comment based on a reconstructed individual patient data analysis of phase 3 trials.